The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

Research reports that in the United States, the number of patients who underwent bariatric procedure decreased by 25%, while ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

BENGALURU/HYDERABAD, Dec 3 (Reuters) - Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of ...

Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

Nearly half of participants in a weight loss program who initiated an antiobesity medication and who consumed alcohol ...

TORINO, Italy I 03, 2024 I Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding ...

Weight loss drugs such as Ozempic and Wegovy are increasingly popular among adults, who have flocked to the new medication as ...

Understanding the role of medical interventions in obesity management is critical to healthcare professionals providing ...

The researchers utilized pooled data from the National Health and Nutrition Examination Survey to assess the overlap between the FDA eligibility standards and the exclusion criteria observed in ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1s have been heralded for their ability to suppress appetite but did you know that GLP-1 is a natural hormone you can stimulate without injections.